Scholz promises support for pharma sector in Germany as Merck invests
Reuters
Published Apr 25, 2024 11:19
BERLIN (Reuters) - German Chancellor Olaf Scholz said he was committed to supporting the pharmaceuticals sector with tax advantages for research and cutting red tape for trials at a ceremony with Merck, which is investing 1.5 billion euros ($1.61 billion) in Germany.
The drugmaker plans to use its new life sciences Advanced Research Centre in the western city of Darmstadt, which it is spending 300 million euros on, to develop services and digital platforms to help scientists work more effectively.
With some 550 employees, it is part of the bigger investment announced in 2022.
Scholz said he wanted Germany to build on a 2.3 billion euro investment by Eli Lilly (NYSE:LLY) in the western town of Alzey and other development plans by Novo Nordisk (CSE:NOVOb), BioNTech (NASDAQ:BNTX), AbbVie (NYSE:ABBV) and Roche (LON:0QQ6) for Europe's biggest economy.
Following the success of BioNTech, which partnered with U.S. giant Pfizer (NYSE:PFE) on its mRNA COVID-19 vaccine, the government has sought to improve conditions for pharma and biotech sectors.
"I want .. the technologies that are needed all over the world to continue to be developed here," Scholz said, adding: "The government will continue to support this new departure with all its strength."
He said recent new policies would help researchers to get access to health data and speed up clinical trials.
($1 = 0.9325 euros)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.